CorMedix Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 46.34 million compared to USD 29.7 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to USD 0.74 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.31 USD | +2.31% | +0.57% | +41.22% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.22% | 292M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023